Abstract Long-term effectiveness and repeated administration of botulinum toxin A are the basis for its use in both neuromuscular disorders and certain painful conditions. Botulinum toxin A has been recently approved for migraine treatment, and its off-label use extends to other craniofacial pain disorders. However, recently it was reported that, after repeated injection, botulinum toxin loses its antinociceptive efficacy in rats. In present study with a similar design, we compared the effects of single and repeated injections of botulinum toxin in formalininduced orofacial pain. No statistically significant differences were found between single or repeatedly treated animal groups. Our results are in line with the clinical experience and suggest that botulinum toxin can be re-administered in orofacial pain treatment.
Introduction
Botulinum toxin A (BTX-A) is used in neuromuscular and autonomous disorders characterized by cholinergic hyperactivity, and in treatment of some forms of pain (Jankovic 2004; Jabbari and Machado 2011) . Important for its clinical application is the long-term effectiveness and repeated use (Naumann et al. 2006) . Its off-label use extends to various painful conditions, such as peripheral neuropathies, low back pain, various types of headache, etc. (Allam et al. 2005; Dodick et al. 2005; Foster et al. 2001; Jabbari and Machado 2011) . BTX-A has been recently approved for chronic migraine treatment (Dodick et al. 2010) .
In experimental animals, it has been shown that BTX-A exhibits long-term reduction of inflammatory acute pain, neuropathic pain, visceral and deep somatic pain (Cui et al. 2004; Bach-Rojecky and Lackovic 2005; Bach-Rojecky et al. 2005; Chuang et al. 2008; Krug et al. 2009 ).
In a recent report its effectiveness was demonstrated in orofacial formalin pain 8 days after the BTX-A pretreatment. However, when toxin was re-administered 42 days after the first treatment, the effect of BTX-A was not reproduced (Piovesan et al. 2011) . Mentioned report that BTX-A loses its analgesic effect upon repeated injection in experimental animals is potentially very important for its clinical use in migraine and in some other chronic pain conditions, where repeated use is of high importance.
The aim of this study was to compare the effects of single or repeated injections of BTX-A in formalin-induced orofacial pain.
Materials and methods

Animals
Adult male Wistar rats (University of Zagreb School of Medicine, Croatia) weighing 300 g at the beginning of experiment were used. Animals were kept in 12 h/12 h light and dark cycle, with unlimited access to food and water. Experiment was conducted according to the European Communities Council Directive (86/609/EEC) and recommendations of the International Association for the Study of Pain (Zimmerman 1983) . Animal procedures were approved by the Ethics Committee of University of Zagreb School of Medicine (Permit No. 07-76/2005-43) .
Drugs 100 units of Botulinum toxin type A (Botox Ò , Allergan Inc., Irvine, CA, USA) were dissolved in 1 ml of 0.9 % saline. 5 U/kg dose was administered unilaterally as 20 ll bolus into the whisker pad tissue using a 27 1/2 gauge needle. 20 ll of 0.9 % saline solution was injected to control rats. Facial formalin injection was carried out using 50 ll of saline-diluted 2.5 % formalin (Kemika, Zagreb, Croatia).
Treatment and behavioral testing
Three months old adult rats were divided into three groups, each consisting of five to six animals. First group of six conscious rats was injected with BTX-A into the left whisker pad tissue, while other two groups were left untreated. After 42 days, first group of rats underwent their second treatment of BTX-A, while the second and third group were injected with BTX-A and saline, respectively. Instead of using two control groups (single and double injection of saline), to reduce the number of animals we used a single control group pretreated only once with saline. In our published experiments, double versus single pretreatment with saline was not found to affect the painful response or BTX-A efficacy (Filipović et al. 2012; BachRojecky and Lacković 2009; Matak et al. 2011) . Period of 42 days between the two BTX-A injections was chosen based on the study of Piovesan et al. (2011) .
After a period of 6 days, orofacial formalin test was performed to assess the antinociceptive activity of BTX-A. Animals were placed inside transparent chambers for 10-min acclimatization period. Following the acclimatization, conscious, restrained rats were injected with formalin into the whisker pad ipsilateral to BTX-A pretreatment and immediately returned to the transparent chamber for a 45-min observation period. Observers were blind to the animal treatment. Observation period was divided into 15 blocks of 3 min, and the number of seconds the animal spent in ipsilateral face rubbing or grooming was measured during phase I (0-12 min) and phase II (12-45 min) of formalininduced pain (Raboisson and Dallel 2004) .
Statistical analysis
Data were represented as mean ± SEM, and analyzed by one-way ANOVA followed by Tukey's HSD test (p \ 0.05).
Results
Injection of BTX-A into whisker pad resulted in reduced movement of ipsilateral whiskers and their backward direction (Fig. 1) . In group receiving two injections of BTX-A no visible reduction of whisker movement was visible 42 days after the first treatment (prior to second BTX-A injection). Whisker paralysis after second BTX-A injection occurred again, as proof of efficiency of re-administered BTX-A (Fig. 1c) .
In orofacial formalin test, phase I of rubbing/grooming behavior was not affected by BTX-A treatment, while phase II in both BTX-A treated groups revealed significant reduction in number of seconds spent rubbing/grooming, in comparison with control (Fig. 2) . There was no statistically significant difference in time of facial grooming between the animals administered once or twice with BTX-A (Fig. 2) .
Discussion
According to experimental results recently published by Piovesan et al. (2011) , BTX-A injections 8 days before formalin test inhibit orofacial pain. However, repeated treatment after 42 days had no effect. This observation could have far reaching clinical consequences because it Fig. 1 Whisker appearance 1 day after administration of a physiological saline, b BTX-A first injection, c BTX-A second injection. Saline and BTX-A (5 U/kg) were administered to the left whisker pad questions the usefulness of repeated injections of BTX-A in pain conditions. Basically, it is also intriguing because it might suggest that, after single injection, BTX-A makes permanent functional changes. Such putative changes might be connected either with mechanism of its uptake by peripheral sensory nerves mediated by SV2 proteins (Mahrhold et al. 2006) , or with the mechanism of antinociceptive action, which is connected with axonal transport from periphery to central sensory nuclei, and likely with central SNAP-25 cleavage (Bach-Rojecky et al. 2009; Matak et al. 2011; Filipović et al. 2012) . It might also suggest immunoresistance to BTX-A or possibly yet unknown long-term effect on synaptic plasticity caused by BTX-A.
However, in contrast to the results from Piovesan et al. (2011) , both single and repeated injection of BTX-A were equally effective in our study, which is in line with the clinical experience in pain treatment. It also suggests that BTX-A does not induce permanent functional changes that could lead to ineffectiveness of repeated injection. The presence of ipsilateral whisker paralysis after second injection of BTX-A verifies that no immune resistance towards BTX-A occurred and the second bolus showed equal effectiveness on neuromuscular junction as in animals that were injected only once, which is in agreement with the repeated clinical use in muscular disorders (Naumann et al. 2006) .
There are few basic differences between the two studies performed. Adult rats of the same age were used in our experiment, whereas the animals used in study from Piovesan et al. (2011) were juvenile when treated with BTX-A and tested with formalin for the first time. In the aforementioned study, formalin was applied twice to the same experimental animals. Cellular protein precipitation and possible permanent peripheral nerve ending damage in rats treated with formalin upon the first nociceptive testing might have interfered with second nociceptive testing or BTX-A uptake into the sensory neurons after second injection. Therefore, in our study, the formalin test was conducted only once in all experimental groups. As described in previous literature phase I of the formalin test, caused by direct stimulation of nerve endings with formalin, is measured for the first 12 min of the test, while phase II represents central sensitization induced by peripheral nerve activity and is measured for the next 33 min (12-45 min) (Raboisson and Dallel 2004) . In our experiments, formalin-induced pain was measured during the whole period of 45 min while Piovesan et al. (2011) measured pain for 30 min only.
Our results did not confirm recent preclinical study from Piovesan et al. (2011) , and suggest that BTX-A can be re-administered in orofacial pain and probably in BTX-A treatment of other forms of pain. 
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